4//SEC Filing
HEGGIE THERESA 4
Accession 0001127602-25-020491
CIK 0000882796other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 8:24 AM ET
Size
11.8 KB
Accession
0001127602-25-020491
Insider Transaction Report
Form 4
HEGGIE THERESA
Director
Transactions
- Exercise/Conversion
Common Stock
2025-08-13$2.91/sh+30,000$87,300→ 95,352 total - Exercise/Conversion
Automatic Stock Option Grant
2025-08-13−40,000→ 0 totalExercise: $5.41From: 2021-05-12Exp: 2030-05-12→ Common Stock (40,000 underlying) - Exercise/Conversion
Common Stock
2025-08-13$5.41/sh+40,000$216,400→ 135,352 total - Sale
Common Stock
2025-08-13$8.51/sh−70,000$595,868→ 65,352 total - Exercise/Conversion
Automatic Stock Option Grant
2025-08-13−30,000→ 0 totalExercise: $2.91From: 2020-05-29Exp: 2029-05-29→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.48 to $8.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001760020
Filing Metadata
- Form type
- 4
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 8:24 AM ET
- Size
- 11.8 KB